ARCHIVES

ODAC Votes Against Adria’s Chemoprotector, Okays Leustatin

This article is from The Cancer Letter archive.

Vol. 18 No. 27 | July 3, 1992

Download PDF Visit The Full Archive

Related Articles

In Brief: Appelbaum Clinical Dib. At Hutchinson; Vogelstein Win Pezcoller Award; Curiel To UAB

July 23, 1993

Durant Suggests Six Efforts Needed For Survival Of Clinical Research

May 30, 1986

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

September 26, 1997

Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting

April 29, 2011

Iressa May Benefit Some Breast Cancer, Studies Find

December 27, 2002

In Brief: Three Comprehensive Centers Have Problems But Aren’t On “Probation”; Amos On Budget

June 9, 1978